Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer

Trial Profile

Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Niraparib (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KEYNOTE-162; TOPACIO
  • Sponsors TESARO
  • Most Recent Events

    • 07 Nov 2017 According to a TESARO Inc. media release, additional data from this trial are expected in the first half of 2017.
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
    • 11 Sep 2017 According to a TESARO media release, data from the study were presented at the 2017 European Society of Medical Oncology (ESMO) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top